UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2009
______________
Stellar Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
______________
Ontario, Canada | 0-31198 | Not Applicable |
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
of Incorporation) | File Number) | Identification No.) |
544 Egerton Street, London, Ontario, Canada, N5W 3Z8
(Address of Principal Executive Office) (Zip Code)
(519) 434-1540
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Stellar Pharmaceuticals Inc. a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that Mr. Martin Thrasher has agreed to join the Stellar board as a new director.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No. |
| Description |
| Stellar Pharmaceuticals Inc. announces Mr. Martin Thrasher has joined their Board of Directors |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| STELLAR PHARMACEUTICALS INC. | |
|
|
|
|
|
|
| By: | /s/PETER RIEHL |
|
| Peter Riehl President and Chief Executive Officer |
|
|
Date: April 22, 2009